
View larger version (25K):
[in a new window]
|
Fig. 6. The P13K/AKT pathway is involved in the TPO-mediated survival effect
observed in clones with low levels of Mpl expression. (A) Proliferation
assays. Cells of clone A were washed three times and left cytokine-deprived or
incubated for 24 hours with 10 ng/ml of TPO, solvent alone (0.14% DMSO), or
the indicated concentration of inhibitors. Cell proliferation was quantitated
by [3H]thymidine incorporation. The results shown are
means±s.d. of triplicate experiments. (B) Western blot analysis of
STAT-5, ERK and AKT activation. Cells from clone A were washed three times,
deprived of cytokines for 3 hours and stimulated with 50 ng/ml of TPO for 15
minutes, DMSO (inhibitor solvent) alone, 50 µM of the MEK inhibitor PD98059
or 10 µM of the P13K inhibitor LY294002. Activation of STAT5, ERK and AKT
was analyzed as described in Fig.
1. ns, no stimulation. (C) Apoptosis analysis. Cells were washed
three times and left cytokine-deprived or stimulated for 22 hours with 10
ng/ml of TPO, solvent alone (0.14% DMSO), or the indicated concentration of
inhibitors. Cells were then labeled with PI and percentages of apoptotic cells
were determined by flow cytometry. Results are representative of two
independent experiments.
|